Clinical Trial Update: A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2 study investigates duvelisib (IPI-145) plus FCR in previously untreated, younger patients with chronic lymphocytic leukemia; the trial is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• COPIKTRA (duvelisib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Rituxan (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2018-12-11